B1045-1g | Sunitinib [557795-19-4] Biotrend

Sunitinib is an oral, multi-targeted and small-molecule inhibitor of receptor tyrosine kinase (RTK) [1].

Sunitinib is a RTK inhibitor against vascular endothelial growth factor receptors (VEGFR1-3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ ), stem cell factor receptor (c-kit), glial cell-line derived neurotrophic factor receptor(RET). Sunitinib has been reported to inhibit the growth in five NPC cell lines (HK1, CNE-2, HON E-1, CNE-1 and C666-1) with the IC50 values of 2.06 ± 0.29μM, 3.45 ± 0.11μM, 4.07 ± 1.07μM, 2.60 ± 0.38 and 7.57 ± 1.74μM, respectively. Apart from these, Sunitinib has been observed to induce apoptosis in NPC cells as well as induce cell cycle arrest at the G0 /G1 phase in HONE-1 and CNE-2 cells. In vivo, Sunitinib treatment could induce a significant reduction in MVD in CNE2 NPC xenograft [1].

References:
[1]Hui EP1, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs. 2011 Dec;29(6):1123-31.

1. Marieke Van Daele, Laura E Kilpatrick, et al. "Characterisation of tyrosine kinase inhibitor-receptor interactions at VEGFR2 using sunitinib-red and nanoBRET." Biochem Pharmacol. 2023 Aug;214:115672. PMID: 37406966
2. Jia-Qi Guo, Chang-Dong Wang, et al. "PDGF‐BB/PDGFRβ Promotes Epithelial‐Mesenchymal Transition by Affecting PI3K/AKT/mTOR‐Driven Aerobic Glycolysis in Wilms' tumor G401 Cells." Cell Biol Int. 2022 Feb 14. PMID: 35165984
3. Bhola PD, Ahmed E, et al. "High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors." Sci Signal. 2020;13(636):eaay1451. PMID:32546544

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	398.47
Cas No.	557795-19-4
Formula	C₂₂H₂₇FN₄O₂
Solubility	insoluble in H2O; ≥19.9 mg/mL in DMSO with gentle warming; ≥3.16 mg/mL in EtOH with gentle warming
Chemical Name	N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
SDF	Download SDF
Canonical SMILES	CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Cell experiment: [1]
Cell lines	Human 786-O and RCC4 cells, murine Renca cells
Preparation method	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
Reaction Conditions	10 μM, 24 hours
Applications	Sunitinib induced RCC tumor cell apoptosis in all three tumor cell lines. It also inhibited cell proliferation in a dose-dependent manner. For concentrations at which sunitinib caused effective tumor cell death; there were corresponding increases in cleaved PARP. Sunitinib treatment (24 h) of 786-O, RCC4 and Renca tumor cells reduced expression of several key anti-apoptotic and pro-proliferation genes, including Cyclin E, Cyclin D1 and Survivin.
Animal experiment: [1]
Animal models	Female BALB/c mice injected with Renca cells
Dosage form	Oral administration, 40, 20, 10 mg/kg body weight, daily
Applications	Sunitinib induced tumor cell apoptosis in vivo as early as 1 day post treatment, which occurred in the presence of apparently intact tumor vessels. There appeared to be more apoptosis in the tumor on days 3 and 11 post treatment, with greater disruption of the tumor vasculature. Sunitinib treatment reduced Stat3 activity and induced tumor cell death as early as one day post treatment.
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References: [1] Xin H, Zhang C, Herrmann A, et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer research, 2009, 69(6): 2506-2513.

Description	Sunitinib is an oral, multi-targeted and small-molecule inhibitor of receptor tyrosine kinase (RTK).
Targets	VEGFR-1	VEGFR-2	VEGFR3	PDGFRα	PDGFRβ	c-kit
IC50		4 nM		69 nM	39 nM	1-10 nM

Purity = 98.00%

Sunitinib [557795-19-4]

Katalog-Nummer B1045-1g

Contact local distributor :

Marke : APExBIO Technology

Contact local distributor :

Background

Product Citation

Chemical Properties

Protocol

Biological Activity

Quality Control

Sie könnten auch an folgenden Produkten interessiert sein: